MNI caged kainic acid
Kainic acid (Cat.No. 0222) caged with the photosensitive 4-methoxy-7-nitroindolinyl group. Generates large inward currents at resting membrane potential upon wide field photolysis in Purkinje neurons. Selectively photoactivates kainate receptors when used in conjunction with an AMPA antagonist, such as GYKI 53655 (Cat.No. 2555). Suitable for uncaging with 300-380 nm excitation. Exhibits rapid uncaging rate relative to ionotropic glutamate receptor activation. Also suitable for two-photon uncaging experiments at 720 nm.
Sold under licence from the Medical Research Council
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||1.95||5 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 389.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.57 mL||12.84 mL||25.68 mL|
|5 mM||0.51 mL||2.57 mL||5.14 mL|
|10 mM||0.26 mL||1.28 mL||2.57 mL|
|50 mM||0.05 mL||0.26 mL||0.51 mL|
References are publications that support the biological activity of the product.
Maier et al (2005) Comparative analysis of inhibitor effects of caged ligands for the NMDA receptor. J.Neurosci.Meths. 142 1 PMID: 15652611
Palma-Cerda et al (2013) New caged neurotransmitter analogues based on methoxy-nitroindole and nitrophenylethoxycarbonyl caging groups are selective for glutamate receptor subtypes. Neuropharmacology 63 624 PMID: 22609535
Palma-Cerda et al (2012) New caged neurotransmitter analogs selective for glutamate receptor sub-types based on methoxynitroindoline and nitrophenylethoxycarbonyl caging groups. Neuropharmacology. 63 624 PMID: 22609535
Passlick and Ellis-Davies et al (2017) Comparative one- and two-photon uncaging of MNI-glutamate and MNI-kainate on hippocampal CA1 neurons. J.Neurosci.Methods. PMID: 29051090
If you know of a relevant reference for MNI caged kainic acid, please let us know.
View Related Products by Target
Keywords: MNI caged kainic acid, MNI caged kainic acid supplier, MNI, caged, compounds, kainic, acid, 4-methoxy-7-nitroindolinyl, photosensitive, neurotoxin, iGluR, ionotropic, glutamate, kainate, receptors, agonists, Caged, Glutamate, Compounds, Kainate, Receptors, 2225, Tocris Bioscience
1 Citation for MNI caged kainic acid
Citations are publications that use Tocris products. Selected citations for MNI caged kainic acid include:
Passlick and Ellis-Davies (2017) Comparative one- and two-photon uncaging of MNI-glutamate and MNI-kainate on hippocampal CA1 neurons. J.Neurosci.Methods. 293 321 PMID: 29051090
Do you know of a great paper that uses MNI caged kainic acid from Tocris? Please let us know.
Reviews for MNI caged kainic acid
There are currently no reviews for this product. Be the first to review MNI caged kainic acid and earn rewards!
Have you used MNI caged kainic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.